Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.

Cancers (Basel) · 2021 · PMC8508505 · PMID 34638369

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nearly significantno p-value reported

In all patients, baseline BCL2 (unfavorable), baseline and Cycle 2 CD8/CNT (favorable), Cycle 2 CD8/INV (favorable; limited sample size), and increases in either CD8/CNT or CD8/INV (favorable; limited sample size) all had significant or nearly significant impacts on pCR.

also in 3,287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.